Prasugrel

Prasugrel
Clinical data
Trade names	Effient, Efient
AHFS/Drugs.com	Monograph
MedlinePlus	a609027
License data	US DailyMed: Prasugrel;
Pregnancy; category	AU: B1; ;
Routes of; administration	By mouth
ATC code	B01AC22 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	≥79%
Protein binding	Active metabolite: ~98%
Elimination half-life	~7 h (range 2 h to 15 h)
Excretion	Urine (~68% inactive metabolites); feces (27% inactive metabolites)
Identifiers
	IUPAC name (RS)-5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-; tetrahydrothieno[3,2-c]pyridin-2-yl acetate;
CAS Number	150322-43-3 389574-19-0 (hydrochloride);
PubChem CID	6918456;
IUPHAR/BPS	7562;
DrugBank	DB06209 ;
ChemSpider	5293653 ;
UNII	34K66TBT99;
KEGG	D05597 ;
ChEBI	CHEBI:87715 ;
ChEMBL	ChEMBL1201772 ;
CompTox Dashboard (EPA)	DTXSID70861544 ;
ECHA InfoCard	100.228.719
Chemical and physical data
Formula	C20H20FNO3S
Molar mass	373.44 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)Oc1cc2c(s1)CCN(C2)C(c3ccccc3F)C(=O)C4CC4;
	InChI InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3 ; Key:DTGLZDAWLRGWQN-UHFFFAOYSA-N ;
	(what is this?) (verify)

Prasugrel, sold under the brand names Effient and Efient, is a medication used to prevent formation of blood clots. It is a platelet inhibitor and an irreversible antagonist of P2Y₁₂ ADP receptors and is of the thienopyridine drug class. It was developed by Daiichi Sankyo Co. and produced by Ube and marketed in the United States in cooperation with Eli Lilly and Company.

Prasugrel was approved for use in the European Union in February 2009,^[2] and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).^[3]

^ "Efient EPAR". European Medicines Agency (EMA). 25 February 2009. Retrieved 5 September 2024.
^ "European Public Assessment Report for Efient" (PDF). EMA. 2009.
^ Baker WL, White CM (2009). "Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes". American Journal of Cardiovascular Drugs. 9 (4): 213–229. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.

[1] "Efient EPAR". European Medicines Agency (EMA). 25 February 2009. Retrieved 5 September 2024.

[EMA-2] "European Public Assessment Report for Efient" (PDF). EMA. 2009.

[3] Baker WL, White CM (2009). "Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes". American Journal of Cardiovascular Drugs. 9 (4): 213–229. doi:10.2165/1131209-000000000-00000. PMID 19655817. S2CID 37160513.

[1]

[2]

[3]